Stay updated with breaking news from Qure Forward Looking. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Patient enrollment expected to begin in first half of 2024LEXINGTON, Mass. and AMSTERDAM, Nov. 29, 2023 -- uniQure N.V. , a leading gene therapy company advancing transformative therapies for...
Patient enrollment expected to begin in first half of 2024...
~ Announced FDA clearance of Investigational New Drug application for AMT-260 in refractory mesial temporal lobe epilepsy ~ ~ On track to provide clinical update from U.S. and European Phase I/II...
~ Announced encouraging interim analysis data from ongoing Phase I/II clinical trial of AMT-130 in Huntington’s disease showing preservation of function compared to baseline and clinical benefits...
~ Walid Abi-Saab, M.D., appointed Chief Medical Officer, will bring extensive track record in leading drug development and execution ~LEXINGTON, Mass. and AMSTERDAM, June 26, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy c...